Comparison Of Surfactant Lung Lavage With Standard Care In The Treatment Of Meconium Aspiration Syndrome

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the role of surfactant lung lavage in the treatment of meconium aspiration syndrome. Aspiration of meconium into the tracheo-bronchial tree with the onset of respiration results in meconium aspiration syndrome (MAS). Aspirated meconium inhibits surfactant function directly and also decreases its synthesis by its toxic effects on type 2 pneumocytes. There is no specific treatment recommended for meconium aspiration syndrome. Numerous studies have shown that exogenous surfactant improves outcome in babies with meconium aspiration. Surfactant replacement alone does not remove meconium from airways and multiple doses may be required .Therefore an effective therapy to improve outcome is crucial in treating infants with meconium aspiration. Surfactant Lung lavage has been shown to be alternative to bolus therapy in treating neonates with meconium aspiration as shown by many pilot studies. So the investigators have decided to study the role surfactant lung lavage in the treatment of meconium aspiration syndrome.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lady Hardinge Medical College
• Treatments: Pulmonary Surfactants

Criteria

Inclusion Criteria:

• Gestation age ≥ 37 week

• Cephalic presentation

• Singleton pregnancy

• Presence of meconium stained amniotic fluid or staining of meconium in skin,umbilical cord or nails.

• Non vigorous babies

• Presence of respiratory distress(Downes score ≥4)

• Presence of meconium below vocal cords or chest x ray suggestive of meconium aspiration

• Age < 2 hours

Exclusion Criteria:

• Major congenital malformations

• Congenital heart disease

• Hydrops fetalis

• Air leaks

• Pulmonary hemorrhage